Literature DB >> 15738353

Low-grade albuminuria and the risks of hypertension and blood pressure progression.

Thomas J Wang1, Jane C Evans, James B Meigs, Nader Rifai, Caroline S Fox, Ralph B D'Agostino, Daniel Levy, Ramachandran S Vasan.   

Abstract

BACKGROUND: It has been postulated that glomerular hyperfiltration and endothelial dysfunction are early features of essential hypertension that may antedate blood pressure elevation. Microalbuminuria, a marker of glomerular hyperfiltration and endothelial dysfunction, has been described in individuals with established hypertension, but its role as a biomarker of preclinical stages of this disease has not been investigated prospectively. METHODS AND
RESULTS: We examined the association between urinary albumin excretion and the risks of hypertension and blood pressure progression in 1499 nonhypertensive individuals (58% women) without diabetes. During a mean follow-up of 2.9 years, 230 participants (15%) developed hypertension and 499 (33%) progressed to a higher blood pressure category (defined by the sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure). In multivariable logistic regressions that adjusted for known risk factors, the urine albumin-creatinine ratio (UACR) was a significant predictor of incident hypertension (adjusted OR 1.20, 95% CI 1.01 to 1.44, per 1-SD increment in log UACR). Compared with those in the lowest UACR quartile, participants in the highest quartile (men: >6.66 mg/g; women: >15.24 mg/g) had an approximately 2-fold risk of developing hypertension (adjusted OR 1.93, P=0.006) and 1.5-fold risk of blood pressure progression (adjusted OR 1.45, P=0.03).
CONCLUSIONS: Urinary albumin excretion predicts blood pressure progression in nondiabetic, nonhypertensive individuals incrementally over established risk factors and at levels well below the conventional threshold for microalbuminuria. UACR may be a useful biomarker for identifying individuals most likely to develop hypertension.

Entities:  

Mesh:

Year:  2005        PMID: 15738353     DOI: 10.1161/01.CIR.0000158434.69180.2D

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  60 in total

1.  Association of kidney function and albuminuria with prevalent and incident hypertension: the Atherosclerosis Risk in Communities (ARIC) study.

Authors:  Minxuan Huang; Kunihiro Matsushita; Yingying Sang; Shoshana H Ballew; Brad C Astor; Josef Coresh
Journal:  Am J Kidney Dis       Date:  2014-08-21       Impact factor: 8.860

Review 2.  Capillary rarefaction as an index for the microvascular assessment of hypertensive patients.

Authors:  Areti Triantafyllou; Panagiota Anyfanti; Athina Pyrpasopoulou; Georgios Triantafyllou; Spyros Aslanidis; Stella Douma
Journal:  Curr Hypertens Rep       Date:  2015-05       Impact factor: 5.369

Review 3.  Prenatal programming-effects on blood pressure and renal function.

Authors:  Eberhard Ritz; Kerstin Amann; Nadezda Koleganova; Kerstin Benz
Journal:  Nat Rev Nephrol       Date:  2011-02-01       Impact factor: 28.314

4.  Obstructive sleep apnea is associated with increased urinary albumin excretion.

Authors:  Michael D Faulx; Amy Storfer-Isser; H Lester Kirchner; Nancy S Jenny; Russell P Tracy; Susan Redline
Journal:  Sleep       Date:  2007-07       Impact factor: 5.849

5.  Non-pressure-related effects of dietary sodium.

Authors:  Guilhem du Cailar; Albert Mimran
Journal:  Curr Hypertens Rep       Date:  2009-02       Impact factor: 5.369

6.  Novel therapeutic approaches to chronic kidney disease.

Authors:  Neeraj Dhaun; David J Webb
Journal:  Br J Clin Pharmacol       Date:  2013-10       Impact factor: 4.335

7.  High normal levels of albuminuria and risk of hypertension in Indo-Asian population.

Authors:  Saleem Jessani; Andrew S Levey; Nish Chaturvedi; Tazeen H Jafar
Journal:  Nephrol Dial Transplant       Date:  2011-05-17       Impact factor: 5.992

8.  Albuminuria and peripheral arterial disease: results from the multi-ethnic study of atherosclerosis (MESA).

Authors:  K Wattanakit; A R Folsom; M H Criqui; H J Kramer; M Cushman; S Shea; A T Hirsch
Journal:  Atherosclerosis       Date:  2008-02-20       Impact factor: 5.162

9.  Impact of the PPAR-gamma2 Pro12Ala polymorphism and ACE inhibitor therapy on new-onset microalbuminuria in type 2 diabetes: evidence from BENEDICT.

Authors:  Salvatore De Cosmo; Nicola Motterlini; Sabrina Prudente; Fabio Pellegrini; Roberto Trevisan; Antonio Bossi; Giuseppe Remuzzi; Vincenzo Trischitta; Piero Ruggenenti
Journal:  Diabetes       Date:  2009-08-31       Impact factor: 9.461

10.  Microalbuminuria measured by three different methods, blood pressure and cardiovascular risk factors in elderly Swedish males.

Authors:  Gösta Florvall; Samar Basu; Johanna Helmersson; Anders Larsson
Journal:  Anal Chem Insights       Date:  2008-09-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.